CD73 expression in normal and pathological human hepatobiliopancreatic tissues. by Sciarra, A. et al.
   
 
 
 
 
Serveur Acade´mique Lausannois SERVAL serval.unil.ch
Author Manuscript
Faculty of Biology and Medicine Publication
This paper has been peer-reviewed but does not include the final publisher
proof-corrections or journal pagination.
Published in final edited form as:
Title: CD73 expression in normal and pathological human
hepatobiliopancreatic tissues.
Authors: Sciarra A, Monteiro I, Me´ne´trier-Caux C, Caux C, Gilbert B,
Halkic N, La Rosa S, Romero P, Sempoux C, de Leval L
Journal: Cancer immunology, immunotherapy : CII
Year: 2019 Mar
Issue: 68
Volume: 3
Pages: 467-478
DOI: 10.1007/s00262-018-2290-1
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.
Cancer Immunology, Immunotherapy
 
CD73 expression in normal and pathological human hepatobiliopancreatic tissues
--Manuscript Draft--
 
Manuscript Number: CIIM-D-18-00224R2
Full Title: CD73 expression in normal and pathological human hepatobiliopancreatic tissues
Article Type: Original Article
Funding Information: FP7 Ideas: European Research Council
(602200)
Dr. Christophe Caux
Abstract: Background: the tumor-expressed CD73 ectonucleotidase generates immune
tolerance and promotes invasiveness via adenosine production from degradation of
AMP. While anti-CD73 blockade treatment is a promising tool in cancer
immunotherapy, a characterization of CD73 expression in human hepatobiliopancreatic
system is lacking.
Patients and methods: CD73 expression was investigated by immunohistochemistry in
a variety of non-neoplastic and neoplastic conditions of the liver, pancreas and biliary
tract.
Results: CD73 was expressed in normal hepatobiliopancreatic tissues with subcellular-
specific patterns of staining: canalicular in hepatocytes, and apical in cholangiocytes
and pancreatic ducts. CD73 was present in all hepatocellular carcinoma (HCC), in all
pancreatic ductal adenocarcinoma (PDAC), and in the majority of intra and
extrahepatic cholangiocellular carcinomas, whereas it was detected only in a subset of
pancreatic neuroendocrine neoplasms and almost absent in acinar cell carcinoma. In
addition to the canonical pattern of staining, an aberrant membranous and/or
cytoplasmic expression was observed in invasive lesions, especially in HCC and
PDAC. These two entities were also characterized by a higher extent and intensity of
staining as compared to other hepatobiliopancreatic neoplasms. In PDAC, aberrant
CD73 expression was inversely correlated with differentiation (p<0.01) and was helpful
to identify isolated discohesive tumor cells. Additionally, increased CD73 expression
was associated with reduced overall survival (HR 1.013) and loss of E-Cadherin.
Conclusions: consistent CD73 expression supports the rationale for testing anti-CD73
therapies in patients with hepatobiliopancreatic malignancies. Specific patterns of
expression could also be of help in the routine diagnostic workup.
Corresponding Author: Laurence de Leval
Lausanne University Hospital
Lausanne, SWITZERLAND
Corresponding Author Secondary
Information:
Corresponding Author's Institution: Lausanne University Hospital
Corresponding Author's Secondary
Institution:
First Author: Amedeo Sciarra
First Author Secondary Information:
Order of Authors: Amedeo Sciarra
Inês Monteiro
Christine Ménétrier-Caux
Christophe Caux
Benoit Gilbert
Nermin Halkic
Stefano La Rosa
Pedro Romero
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Christine Sempoux
Laurence de Leval
Order of Authors Secondary Information:
Author Comments:
Additional Information:
Question Response
Please provide one or two short
sentences highlighting what makes your
manuscript especially interesting. This
précis is meant for our table of contents
and must not exceed 250 characters,
including spaces. Please include an
identical précis in your manuscript text,
following the abstract
Translational investigation of CD73 expression in hepatobiliopancreatic malignancies
suggests a rationale for testing anti-CD73 therapies in these tumors and its use in the
routine diagnostic pathological workup.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
1 
CD73 expression in normal and pathological human hepatobiliopancreatic 
tissues 
Amedeo Sciarra1*, Inês Monteiro1*, Christine Ménétrier-Caux2, Christophe Caux2, 
Benoit Gilbert1, Nermin Halkic3, Stefano La Rosa1, Pedro Romero4, Christine 
Sempoux1**, and Laurence de Leval1** 
* First co-authors; ** Co-corresponding authors
1. Service of Clinical Pathology, Institute of Pathology, Lausanne University Hospital,
Lausanne, Switzerland. 
2. Innovation in Immuno-monitoring and Immunotherapy Platform (PI3), Léon Bérard
Cancer Center, Lyon, France. 
3. Department of Visceral Surgery, Lausanne University Hospital, Lausanne,
Switzerland. 
4. Department of Oncology, Faculty of Biology and Medicine, University of Lausanne,
Lausanne Switzerland. 
Correspondence: Prof. Laurence de Leval MD PhD and Prof. Christine Sempoux MD 
PhD, Service of Clinical Pathology, Institute of Pathology, Lausanne University 
Hospital, rue du Bugnon 25, CH-1011 Lausanne, Switzerland, 
laurence.deleval@chuv.ch, christine.sempoux@chuv.ch. 
ORCID: 
Amedeo Sciarra 0000-0002-7550-0312 
Christine Sempoux 0000-0003-1375-3979 
Laurence de Leval 0000-0003-3994-516X 
Manuscript
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
2 
NOTE ON PREVIOUS PUBLICATION 
Part of the current work was presented as a poster at the 30th European Congress of 
Pathology, held by the European Society of Pathology in Bilbao, Spain on 8-12 
September 2018 (poster 014, session PS14). Poster abstract, entitled “CD73 in 
hepatobiliopancreatic system: a potential target for immunotherapy and additional tool 
for the pathological diagnosis” was published on Virchows Arch vol.473 (Suppl. 1): 
S124, 2018. [1] 
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ABSTRACT 
Background: the tumor-expressed CD73 ectonucleotidase generates immune 
tolerance and promotes invasiveness via adenosine production from degradation of 
AMP. While anti-CD73 blockade treatment is a promising tool in cancer 
immunotherapy, a characterization of CD73 expression in human 
hepatobiliopancreatic system is lacking. 
Patients and methods: CD73 expression was investigated by immunohistochemistry 
in a variety of non-neoplastic and neoplastic conditions of the liver, pancreas and 
biliary tract. 
Results: CD73 was expressed in normal hepatobiliopancreatic tissues with 
subcellular-specific patterns of staining: canalicular in hepatocytes, and apical in 
cholangiocytes and pancreatic ducts. CD73 was present in all hepatocellular 
carcinoma (HCC), in all pancreatic ductal adenocarcinoma (PDAC), and in the majority 
of intra and extrahepatic cholangiocellular carcinomas, whereas it was detected only 
in a subset of pancreatic neuroendocrine neoplasms and almost absent in acinar cell 
carcinoma. In addition to the canonical pattern of staining, an aberrant membranous 
and/or cytoplasmic expression was observed in invasive lesions, especially in HCC 
and PDAC. These two entities were also characterized by a higher extent and intensity 
of staining as compared to other hepatobiliopancreatic neoplasms. In PDAC, aberrant 
CD73 expression was inversely correlated with differentiation (p<0.01) and was helpful 
to identify isolated discohesive tumor cells. Additionally, increased CD73 expression 
was associated with reduced overall survival (HR 1.013) and loss of E-Cadherin. 
Conclusions: consistent CD73 expression supports the rationale for testing anti-
CD73 therapies in patients with hepatobiliopancreatic malignancies. Specific patterns 
of expression could also be of help in the routine diagnostic workup. 
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pancreatic carcinoma, cholangiocarcinoma. 
 
PRÉCIS 
Translational investigation of CD73 expression in hepatobiliopancreatic malignancies 
suggests a rationale for testing anti-CD73 therapies in these tumors and its use in the 
routine diagnostic pathological workup. 
 
ABBREVIATIONS 
ACC: acinar cell carcinoma 
BilIN: bile duct intraepithelial neoplasia 
EMT: epithelial to mesenchymal transition 
HIF1: hypoxia-inducible factor 1 
ICC: intrahepatic cholangiocellular carcinoma 
IPMN: intraductal papillary mucinous neoplasms 
MCA: mucinous cystadenoma 
PanIN: pancreatic intraepithelial neoplasia 
PanNEC: pancreatic neuroendocrine tumor and carcinoma 
PanNET: pancreatic neuroendocrine tumor 
PDAC: pancreatic ductal adenocarcinoma 
TC: tumor cells 
TIMC: tumor infiltrating mononuclear cells  
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INTRODUCTION 
CD73, encoded by NT5E gene, is an ectoenzyme with a 5’-nucleotidase activity, 
converting extracellular ATP-derived AMP to adenosine. [2] Expression of this enzyme 
was initially described in endothelial cells, and subsequent human transcriptome and 
proteome analyses have shown that it is present in most normal tissues. [3-6] 
 In physiological conditions, adenosine is present in the extracellular space at 
low levels, while under hypoxia or inflammation extracellular adenosine levels can 
increase. [7, 8] In these circumstances, adenosine attenuates the inflammatory and 
immune responses, prevents collateral tissue damage, stimulates angiogenesis and 
promotes cell-matrix interactions and cell migration. [7-10] 
 In tumors, the role of CD73 was investigated with animal models of solid 
neoplasms, including tumor xenografts (ectopic and orthotopic), and with murine and 
human tumor cell lines. Collectively, these studies showed that CD73 can influence 
the tumor microenvironment through enzymatic and non-enzymatic functions, by 
sustaining cell proliferation, angiogenesis, reducing cell-cell adhesion, promoting 
epithelial to mesenchymal transition (EMT), and generating immune tolerance. [11-13] 
Several studies have identified CD73 expression in human malignant neoplasms, 
such as glioma, melanoma, breast, colon, pancreas, kidney, bladder, prostate and 
ovarian cancers. In these studies, various materials have been examined (cell lines, 
tumor tissues), and different methods were used to assess CD73 mRNA or protein 
levels, by flow cytometry, western blot or IHC. [3, 4, 7, 10, 14-24] 
 The mechanisms underpinning the deregulation of CD73 expression in tumors 
are not completely characterized, but may involve endocrine modulation by 
oestrogens or thyroid hormones, hypoxia (via the hypoxia-inducible factor-1α, HIF1 
α), and pro-inflammatory cytokines, such as IFN-α and IFN-β (upregulation) or IFN-γ, 
lipopolysaccharides, and glutamic acid (downregulation). [25] Other authors 
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demonstrated in human melanoma cell lines that NT5E is subject to CpG methylation-
dependent transcriptional silencing. In the same study, on clinical cases, it was shown 
that metastases developed more commonly from primary melanomas lacking NT5E 
promoter methylation. [26] A potentially adverse prognostic role of CD73 has also 
been highlighted in a pooled meta-analysis of gene expression analysis and IHC data 
from studies including ovarian, renal, gastrointestinal, breast and prostate cancer 
cases and in a study on human malignant melanoma from our group. [27, 28]  
Data generated from public datasets accessible from cBioPortal show 
consistent CD73 mRNA expression in all investigated tumor types, at variable levels 
(Fig. S1). [29, 30] Notably, potentially interesting results could be expected from the 
evaluation of CD73 protein expression in hepatobiliopancreatic tumors, because high 
CD73 mRNA levels are found in liver and pancreatic cancer. [29, 30] Moreover, 
integrative analysis of TCGA RNA samples of pancreatic cancer suggests an 
unfavorable prognostic value of higher CD73 mRNA levels. [6] However, to date, no 
study has characterized CD73 expression in the hepatobiliopancreatic system (normal 
and pathological), or in tumor-infiltrating mononuclear cells in neoplasms occurring in 
these sites. 
 The aims of this study were to examine the expression of CD73 in normal, 
inflammatory and neoplastic specimens of human liver, extrahepatic biliary tract and 
pancreas, in order to define baseline and tumor-related expression of this molecule, 
to assess the potential use of CD73 IHC as a complementary diagnostic tool in 
histopathology, and to explore future perspectives for CD73 targeted therapies in 
hepatobiliopancreatic malignancies. 
 
MATERIALS AND METHODS 
Cases under study 
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Formalin-fixed paraffin-embedded samples from 202 surgical specimens, 
representative of various hepatobiliopancreatic non-neoplastic and neoplastic 
conditions, were retrieved from the archival files of the Institute of Pathology of the 
Lausanne University Hospital (1996-2017). In addition, 19 cases of acinar cell 
carcinoma (ACC), published in a previous study were obtained from the Ospedale di 
Circolo, Varese, Italy. [31] For neoplastic samples, the baseline clinico-pathological 
features extracted from medical and pathological records are summarized in Supp. 
Table 1, and overall survival data were recorded. When necessary, the TNM staging 
classification was reviewed and updated to be consistent with the 2017 edition. [32] 
 
Immunohistochemistry 
IHC was performed using a CD73-specific (D7F9A, rabbit monoclonal, #13160, Cell 
Signaling) and an E-Cadherin- specific (NCH-38, mouse monoclonal, #M3612, Agilent 
Dako) antibodies using the Ventana BenchMark automated stainer. Briefly, for CD73 
deparaffinized slides were pre-treated with CC1 for 60 minutes and incubated for 60 
minutes at 37°C (dilution 1:100), while for E-Cadherin, they were pre-treated with CC1 
for 30 minutes and incubated for 32 minutes at 37°C (dilution 1:50). The Ultraview 
DAB detection kit (ref. 760-500) was used in both cases. In most representative cases 
(n=10) an additional double staining for CD73 and E-Cadherin was also performed 
(same antibodies and dilution, Ventana DISCOVERY yellow and purple detection kits 
respectively).  For CD73, an external control (reactive tonsil) was stained in each batch 
and positive stain in dendritic and mantle cell was verified, as previously reported. [28, 
33]  
An adjacent section was stained with Haematoxylin and Eosin (H&E) (Ventana 
HE 600 system) for morphological reappraisal and to assist IHC interpretation. 
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Pathological analysis 
H&E staining recuts were examined to confirm the original diagnoses, and for 
evaluation of the density of tumor infiltrating mononuclear cells (TIMC). TIMC density 
was evaluated within and at the periphery of the invasive tumors and scored as 
follows: 1: TIMC scattered; 2: TIMC easy to find; 3: TIMC extension similar to that of 
tumor cells (TC) (Fig. S2A-C), following recommendations previously reported. [34] 
For IHC, in non-neoplastic specimens, we recorded: the type of cells showing 
CD73 expression; the subcellular staining pattern and distribution; and the intensity of 
staining, scored as follows: 1: mild, 2: moderate and 3: strong. In neoplastic specimens 
we recorded: the percentage of CD73+ TC (and used a 5% cut off to consider a 
positive case); and the subcellular staining pattern, distribution and intensity, scored 
as 1 to 3 as for the normal counterparts (Fig. S2D-F). Endothelial and stromal staining 
was used as internal control. Since staining intensity was frequently heterogeneous, 
when areas representing >10% of the lesion stained differently, an average value was 
used. We also evaluated the number of cases with at least 5% of TC with intensity=3 
and the percentage of CD73+ TIMC. E-Cadherin staining was recorded as preserved 
or reduced/loss. Slides were evaluated independently by two junior pathologists (A. 
Sciarra and I. Monteiro) and consensus review for harmonization of results was 
performed with two senior pathologists (C. Sempoux and L. de Leval). 
 
Statistical analysis 
All variables were reported as numbers and percentages. Continuous variables were 
summarized as median with range, and categorical variables as frequency and 
percentage. Comparisons between groups of quantitative variables were performed 
using the Mann-Whitney U or Kruskal-Wallis test. Comparisons among groups of 
qualitative variables were performed using χ2 and Fisher exact tests. Survival 
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analyses included univariate and multivariate cox regression model and log-rank test. 
All tests were two-sided and used a significance level of 0.05. All analyses were 
performed with SPSS 22.0 (®2013 SPSS Inc., Chicago, IL, USA).  
 
 
RESULTS 
Liver 
In normal liver (n=5), and in viral and alcoholic chronic liver disease with cirrhosis 
(n=5), CD73 was consistently expressed in all hepatocytes with a canalicular pattern 
of staining and with moderate intensity (score=2) (Fig. S3A). In portal tracts, bile duct 
epithelium showed a variable fraction of cells with a mild apical pattern of staining (Fig. 
S3B). The endothelium of sinusoids, portal venules and arteries, and the perineurium, 
were consistently CD73 positive (intensity score 2). A few lymphoid cells displayed 
mild to moderate expression. Structural connective tissue and fibrous septa were 
unstained, both in normal and fibrotic livers. 
 
HCC (n=24) 
All cases of HCC featured CD73 expression in at least a fraction of TC (10 to 95%, 
median 80%) (Table 1). As compared to the normal liver, neoplastic hepatocytes 
systematically showed an aberrant pattern of CD73 staining (Fig. 2A): beside the 
preserved canalicular expression, an extension to other parts of the membrane and a 
cytoplasmic staining were present (Fig. 2B). Occasionally, CD73-negative areas were 
observed (Fig. 2C). Intensity of staining was stronger than in non-neoplastic liver, often 
increased in TC at the interface with fibrosis (Fig. 2D). TC with intensity=3 were noted 
in 15/24 (63%) cases. High (G3) vs low grade (G1-G2) HCC significantly showed a 
higher number of CD73+ TC (p=0.013). 
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Intrahepatic cholangiocellular carcinoma (ICC) (n=24) 
CD73 was expressed in 14/18 (78%) ICC, in 10% to 95% of TC (median 70%) (Table 
1). Malignant cholangiocytes showed an apical staining pattern, similar to that seen in 
their non-neoplastic counterparts (Fig. 3A). Extension of the staining to other parts of 
the membrane or to the cytoplasm was observed less frequently (8/14 cases, 57%) as 
compared to HCC cases (Fig. 3B). Intensity of staining was heterogeneous (Fig. 3C), 
slightly stronger than on normal bile ducts (median intensity 1.5 vs 1), and TC with 
intensity=3 were only focally observed, without a specific topographic distribution. 
CD73 expression was unrelated to tumor grade. High (G3) vs low grade (G1-G2) ICC 
significantly showed a higher number of CD73+ TC per case (p=0.03) and comprised 
a larger proportion of cases with TC strongly positive for CD73 (p=0.047). 
 
Extrahepatic biliary tract 
In normal extrahepatic biliary tract (n=7) and gallbladder (n=7), a variable fraction of 
cholangiocytes showed a mild apical, CD73 staining (Fig. S3C and S3D). 
 
Extrahepatic bile duct intraepithelial neoplasia (BilIN) and carcinoma (n=25) 
BilIN lesions adjacent to invasive carcinoma were present in 9 cases, with 5 of them 
showing a focal apical CD73 staining (Fig. 3D) (Table 1). 
 By contrast, all invasive bile duct carcinomas showed CD73 staining, involving 
15-95% of the tumor cells (median 50%) (Table 1). Malignant cholangiocytes 
presented a staining pattern similar to that of normal cholangiocytes (Fig. 3E), with 
aberrant extension to other parts of the membrane or cytoplasm in 7/15 (47%) cases 
(Fig. 3F). Intensity was mild to moderate (score 1 or 2) with a median value of 1.5 (1-
2.5). TC with intensity=3 were noted in 6/15 (40%) cases. High (G3) vs low-grade (G1-
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G2) bile duct carcinomas comprised a larger proportion of cases with TC strongly 
positive for CD73 (p=0.031). 
 
Pancreas 
In normal pancreas (n=6), and in chronic pancreatitis (n=4), intralobular and 
extralobular pancreatic ducts, including the Wirsung canal, featured a variable 
proportion of CD73+ epithelial cells with an apical pattern of staining, similar to that 
observed in biliary ducts (Fig. S3E). Acinar cells and Langerhans islet cells were 
consistently CD73-negative (Fig. S3F). A meshwork of CD73 positive capillaries and 
supporting stroma was seen in the background. In chronic pancreatitis, the collagen 
stroma intervening between lobules showed a mild to moderate CD73 staining. 
 
Pancreatic intraepithelial neoplasia (PanIN), pancreatic ductal adenocarcinoma 
(PDAC) (n=42) and PDAC metastases (n=12) 
PanIN lesions adjacent to invasive carcinoma were present in 14/42 cases. CD73 was 
mildly expressed in 12 of them, in a fraction of the dysplastic cells (10-95%), with an 
apical staining pattern (intensity score=1) (Fig. 4A) (Table 2). No variation in CD73 
staining was noted according to the degree of dysplasia. 
 By contrast, CD73 was expressed in all cases of invasive PDAC, with a median 
value of 80% of positive TC (5-95%) and a median intensity of 2 (1-3). TC with 
intensity=3 were noted in most of cases (26/42, 62%) (Table 1). 
Strikingly, differences in staining pattern were observed according to tumor 
architecture, prompting a separate analysis of CD73, based on tumor grade. Among 
the 42 PDAC cases, 17 showed a pure well differentiated (G1-G2) histology, 5 a pure 
poorly differentiated (G3) histology, and 20 comprised both G1-G2 and G3 areas that 
were analysed separately (Fig. S4). All 37 G1-G2 PDAC areas were CD73 positive 
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with an apical staining similar to that of pancreatic ducts (Fig. 4B) in 23/37 (62%) 
cases, and a staining extended to the membrane and/or to the cytoplasm in the 
remaining cases (Fig. 4C). Conversely, the aberrant CD73 expression was present in 
all G3 PDAC areas (n=25) (Fig. 4D), at variance with G1-G2 areas (p<0.001) (Table 
2). Distinctively, poorly differentiated discohesive TC had strong cytoplasmic CD73 
staining (Fig. 4E). In that respect, CD73 IHC was useful to highlight isolated 
discohesive TC in otherwise better differentiated areas (Fig 4F). Moreover, in G3 
PDAC areas, both extent and intensity of staining were higher than in G1-G2 areas: 
40-95% vs 5-95%, (p<0.001) and 1.5-3 vs 1-2.5, (p<0.001), respectively. All G3 PDAC 
showed intensity=3 areas, vs 41% of G1-G2 PDAC (p<0.001).  
 We also examined 10 nodal metastases and 2 peritoneal metastases, obtained 
from the same patients. These specimens showed pure G1-G2 or G3 differentiation 
(Fig. S4), and the same correlation between expression pattern of CD73 and grade as 
in primary lesions was observed (Table 2 and Supp. Table 2): apical staining in all 8 
G1-G2 and aberrant in all 4 G3 metastatic deposits (Fig 4G and 4H). Again, isolated 
TC were easily identified by CD73 staining (Fig. 4I). 
 
Mucinous pancreatic neoplasms (n=18) 
Focal and apical mild to moderate CD73 staining was observed in 1/5 (20%) mucinous 
cystadenomas (MCA, Fig. S5A) and in 10/13 (77%) intraductal papillary mucinous 
neoplasms (IPMN), independently of the degree of dysplasia (Fig. S5B and Table 1). 
 
Pancreatic neuroendocrine tumor and carcinoma (PanNET/PanNEC) (n=20/3) 
Heterogeneous CD73 expression was seen in 7/20 (35%) PanNET (1/7 G1, 5/12 G2, 
1/1 G3) and 1/3 (33%) PanNEC, with a membranous and cytoplasmic pattern of mild 
or moderate intensity (score 1 or 2), with no peculiar topographic distribution (Fig.S5C) 
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and in a variable fraction of cells (10-95%), with few TC with intensity=3 in only one 
PanNET G2 case (Table 1). No relationship was found with grade in PanNET group 
of cases. 
 
ACC (n=19) 
Most ACCs (17/19) were completely negative for CD73 expression in the presence of 
adequate internal controls (Fig. S5D). Only two cases exhibited a focal (≤10% of TC) 
CD73 expression, with a membranous and cytoplasmic mild to moderate staining 
pattern, mainly localized at the interface with peritumoral stroma (Table 1). 
 
TIMC 
Results for TIMC are detailed in Table 3. Overall, low TIMC infiltration (quantity 
score=1) was observed in 114/157 (73%) specimens of invasive tumors. In particular, 
this feature was observed in almost all cases of extrahepatic biliary tract carcinoma, 
PanNET/PanNEC and ACC. Score 3 TIMC infiltrates were only present in 4 HCC and 
3 PDAC cases. These were characterized by large sheets of mononuclear infiltrating 
cells within and at the border of tumor, without other specific morphological or clinical 
characteristics. In all cases, the percentage of CD73 positive TIMC was low (≤20%), 
and median values were ≤5% for all histotypes, even in score 3 TIMC cases.  
 
Prognostic value of CD73 expression in hepatobiliopancreatic malignancies 
Overall survival (OS) data were available for 145 patients (24 HCC, 24 ICC, 19 bile 
duct carcinoma, 38 PDAC, 21 PanNET/PanNEC and 19 ACC), with a median follow-
up of 17 (0.2-107) months. In univariate analysis, a reduced OS for 
hepatobiliopancreatic malignancies was significantly associated with a pT3-T4 TNM 
stage (HR=2.242, p=0.016), nodal invasion (HR=4.283, p<0.001), microvascular 
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invasion (HR=2.760, p=0.009), G2-G3 histology (HR=2.463, p=0.013), as well as an 
increased percentage of CD73+TC% (HR=1.010, p=0.032), CD73 intensity 
(HR=1.489, p=0.063) and CD73+TC% intensity=3 (HR=1.026 p=0.006) (Supp. Table 
3). Multivariate analysis identified nodal invasion (HR=4.423 [96%IC 1.937 – 10.1], 
p<0.001), G2-G3 histology (HR=2.381 [95% IC 1.153- 4.917], p=0.019), and an 
increased percentage of CD73+TC% (HR=1.013 [95% IC 1.001 - 1.025], p=0.032) as 
independent factors affecting the OS. A 50% CD73+TC cut off separated cases with 
longer (<50% CD73+TC) and reduced (≥50% CD73+TC) OS (p=0.041, long-rank test) 
(Fig.S6). Cox univariate subgroup analyses for individual hepatobiliopancreatic 
malignancy are indicated in Supp. Table 4. Specifically, a significant association of OS 
and CD73+TC% was observed in HCC and PDAC subgroups. 
 
Putative EMT phenotype (loss of E-Cadherin expression) in CD73+ PDAC 
E-Cadherin expression was analysed in the 42 PDAC cases. Areas showing ductal 
morphology (G1-G2) were characterized by a preserved membranous E-Cadherin 
staining in all cases. In areas displaying poorly differentiated morphology (G3), a 
consistent fraction of CD73 positive discohesive single cells were also characterized 
by a complete or near complete loss of the canonical membranous E-Cadherin 
expression, consistent with an EMT phenotype (Fig.S7). 
 
DISCUSSION 
Recent discovery of CD73 immunosuppressive and pro-angiogenic functions 
promoting onset and progression of cancer has raised significant hope in the future 
development of targeted anti-CD73 treatments. [7, 35] However, to achieve this aim, 
many technical, preclinical and clinical obstacles have still to be overcome, including 
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the precise characterization of CD73 expression in different normal and neoplastic 
human tissues. 
In this study, we focused on the hepatobiliopancreatic system, selecting a large 
series of different neoplasms, and corresponding normal tissues and preneoplastic 
conditions and used IHC. We demonstrated CD73 protein expression in normal liver, 
biliary tract and pancreas, in accordance with data generated in human transcriptome 
and proteome analyses. [5, 6] More specifically, in addition to the ubiquitous 
endothelial staining, we found a restriction to different cell types, with distinct 
subcellular patterns of staining. In hepatocytes, bile and pancreatic ducts, CD73 was 
expressed with a polarized, apical pattern, corresponding to the canalicular pole of 
hepatocytes or the luminal pole of ductal cells. This “baseline” expression pattern was 
maintained in inflammatory conditions (cirrhosis, pancreatitis), and in non-invasive 
lesions (BilIN, mucinous pancreatic neoplasms, PanIN). In invasive lesions, different 
patterns of CD73 IHC were observed, in general encompassing an increase in both 
the extent and intensity of staining that we defined as an “aberrant pattern”. 
HCC and PDAC were the two entities exemplifying this feature. In these tumors, 
the normal CD73 polarized distribution (canalicular for the liver and apical for 
pancreatic ducts) shifted to a more diffuse distribution, with extended membrane 
staining and a cytoplasmic accumulation. 
A cytoplasmic presence of 5’ nucleotidase was first documented with immunoelectron 
analyses of rat liver and kidney, colocalized in multivesicular endosomes, lipoprotein 
particles, and Golgi membrane. [36] According to the human protein atlas, a cytosolic 
expression of CD73 has been identified by immunofluorescence microscopy in human 
adherent myoblast, epidermoid carcinoma, and glioblastoma cell lines, with lower 
levels as compared to those in the plasma membrane. [5] Therefore, the absence of 
a cytoplasmic IHC staining in normal tissues could reflect intracellular CD73 levels 
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below the limit of detection, while the cytoplasmic accumulation of CD73 in tumors 
cells coupled with an extended membranous staining, may be due to a strongly 
increased transcriptional activity of NT5E in these entities. For PDAC, this 
phenomenon is similar to that observed for MUC1 expression, previously reported as 
a useful marker to distinguish invasive PDAC from reactive alterations. [37] 
Accordingly, CD73 pattern of staining could be eventually tested as a diagnostic tool, 
knowing that intense and diffuse membranous/cytoplasmic staining was observed only 
in neoplastic cases (specificity=100%). We also found CD73 staining very useful to 
highlight isolated, discohesive PDAC TC dispersed in desmoplastic stroma or in lymph 
nodes, that could be missed on standard analysis on H&E sections. As such, in the 
routine diagnostic workup of a pancreatic specimen, a pre-operative biopsy or a 
surgical sample, an aberrant CD73 pattern of staining might favour the diagnosis of 
PDAC over reactive ductal atypia in the context of chronic pancreatitis. However, it 
should be stressed that CD73 IHC can be less helpful in highlighting G1-G2 tumors, 
as these showed in most of cases an apical pattern of staining similar to normal 
pancreatic ducts. HCC and PDAC were also characterized by the highest proportion 
of CD73+ TC and the strongest intensity of staining. Clusters of cells with intense 
staining were observed in >50% of HCC and PDAC cases, suggesting that CD73 is 
deregulated and potentially targetable in these two entities. Blockade of CD73 activity 
in these two neoplasms could be of particular interest, as both HCC and PDAC are 
considered to be recalcitrant to conventional treatments and their responsiveness to 
immunotherapy with PD-L1 inhibitors is debated [38-41] 
 The immune suppressive effect of CD73 is mediated by the extracellular 
concentration of adenosine, which interacts with signals to immune cells via its ligation 
to adenosine receptor (AR) and, particularly, to A2AR. [42] Accordingly, it has been 
demonstrated in in vitro models that A2AR stimulation inhibits a large spectrum of 
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inflammatory activities including the proliferation, cytokine production and cytotoxicity 
of T cells. [43, 44] The restoration of T cell proliferation and activity could be an 
important endpoint in HCC and PDAC as these entities have been consistently 
reported as characterized by an impaired T cell infiltrate, via increased TGF-beta 
levels and switching from Th1 to Th2-type cytokine secretion. [45, 46]  Moreover, a 
therapeutic CD73 blockade may prevent its non-enzymatic direct effects on tumor 
cells leading to reduced cell adhesion and interaction with extracellular matrix. [10] 
Thus, CD73 blockade could be particularly helpful in these entities, if eventually 
incorporated in combined immunotherapy strategies. [47] 
Refining the results from a previous study, which suggested increased CD73 
expression in neoplastic vs normal human pancreas using functional proteomic 
analysis and IHC, we observed that CD73 expression increased in parallel with 
morphological tumor grade and that an aberrant pattern was typically observed in 
poorly differentiated discohesive PDAC cells, suggesting that this molecule is also a 
marker of biological aggressiveness. [48] Notably, this was the only significant 
correlation that we observed between CD73 IHC and other clinico-pathological 
variables. One explanation could be found in the tumoral microenvironment of poorly 
differentiated tumors. In these conditions, TC suffer from hypoxic stress and adaptively 
express protective molecules such as HIF-1, which is known to positively regulate 
CD73 expression. [7, 49, 50] As the amount of released adenosine also depends on 
the extent and severity of ischemia/necrosis, we sought to assess if CD73 expression 
was increased at the interface with necrotic areas. However, in our specimens, 
necrosis was focal and the relationship between ischemia/necrosis and CD73 
expression was not evaluable. [51] 
One additional possible explanation of the CD73 protein overexpression could 
be found in EMT. Indeed, increased CD73 levels were detected in cell lines of breast 
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carcinoma undergoing EMT-induced by TGF-β. [52, 53] While EMT is a hallmark of a 
more aggressive phenotype and is also induced by HIF-1, TGF-β is secreted by 
tumors and has an immunosuppressive role similar to that of CD73. [54-56]. 
Interestingly, EMT has been associated with a shift from the apical-basolateral polarity 
of epithelial cells towards the anterior-posterior (front-rear) polarity of motile cells, a 
feature similar to the switch from basal to aberrant extended CD73 membranous 
staining we observed. [57] A potential link between CD73 and EMT-like phenotype 
has been recently presented in a mouse model of melanoma showing that, in relapsed 
melanomas with a mesenchymal-like phenotype, CD73 transcription was induced 
through the cooperation of released pro-inflammatory cytokines and activating MAPK 
mutations through the c-Jun/AP-1 transcription factor complex. [58] In accordance with 
these data, a fraction of CD73 strongly positive isolated tumor cells showed a loss of 
E-Cadherin, one of the most frequently investigated putative EMT biomarker in 
pancreatic cancer, suggesting that CD73 expression could be, at least partially, 
associated with an EMT phenotype. 
Deregulated, aberrant CD73 expression was less frequently observed in 
tumors derived from bile ducts (intra and extrahepatic), where the main pattern was 
still apical and the proportion and intensity of CD73+ TC were lower. Accordingly, 
TCGA network derived data show lower CD73 mRNA expression in these entities than 
in HCC and PDAC. [29, 30] We also observed that most of ACC (89%) and 
PanNET/PanNEC (57%) did not express CD73, this feature epitomizing the negative 
basal pattern of normal pancreatic acinar and endocrine cells. Our data regarding 
PanNET/PanNEC are in accordance with those from a recent report indicating that 
>70% of gastrointestinal NETs and 40% of NECs are CD73 negative. [59] As 
pancreatic neuroendocrine neoplasms are considered a heterogeneous entity, with 
PanNEC being molecularly more similar to PDAC than to PanNET, CD73 should be 
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investigated in more cases to better understand if the CD73 expression is different in 
PanNET vs PanNEC. [60]  
Interestingly, a recent pooled meta-analysis has also suggested the prognostic 
role of CD73 in many tumors, including some gastrointestinal malignancies. [27] In 
accordance with these results, in our series, an increased CD73 expression -in terms 
of percentage of positive cells- was also associated with a reduced overall survival, 
even if with a very limited impact (HR 1.013). Because CD73 was early identified as 
an immunoregulatory molecule expressed by lymphocytes, we also evaluated CD73 
expression in TIMC. In this series, TIMC quantity was generally low, in accordance 
with the notion that hepatobiliopancreatic tumors are not strongly immunogenic, 
except in rare morphological variants. [61, 62] The fraction of CD73 positive TIMC was 
also consistently low, independently of the extent of the inflammatory infiltrate, tumor 
histotype and pathological variables. This result supports the notion that the neoplastic 
cells represent the main source of CD73 in these tumors. [7]  
In conclusion, CD73 is consistently expressed in the majority of 
hepatobiliopancreatic malignancies, with histotype-specific pattern of staining. 
Strongest and aberrant expression in poorly differentiated tumors, and, particularly, in 
HCC and PDAC, make these lesions most suitable for a targeted treatment. 
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FIGURES LEGEND 
 
FIGURE 1. CD73 in hepatocellular carcinoma.  
A, Hepatocellular carcinoma showing strong canalicular and moderate membranous 
and cytoplasmic staining. B, Hepatocellular carcinoma comprising areas showing 
heterogeneous CD73 expression ranging from cytoplasmic, canalicular and 
membranous expression (lower left to upper right). C, Hepatocellular carcinoma 
mostly negative for CD73 with a cluster of CD73-positive tumor cells. D, Periphery of 
a hepatocellular carcinoma showing strongly positive tumor cells at the interface with 
peritumoral fibrosis (asterisk). 
 
 
 
 
 
FIGURE 2. CD73 in intrahepatic cholangiocellular carcinoma, BilIN and 
extrahepatic bile duct carcinoma.  
A, Cholangiocellular carcinoma showing positive neoplastic glands (arrows), showing 
a mild apical staining admixed with CD73 negative glands. B, Cholangiocellular 
carcinoma showing moderate intensity homogeneous membranous staining. C, 
Cholangiocellular carcinoma showing diffuse CD73 staining ranging from mild to 
strong in intensity. D, BilIN showing very focal apical staining in dysplastic cells 
(arrows). E, Bile duct carcinoma showing mild to moderate apical staining. F, Bile duct 
carcinoma comprising an area with strong, membranous and cytoplasmic CD73 
staining. 
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FIGURE 3. CD73 in PanIN, primary and metastatic pancreatic adenocarcinoma. 
A, PanIN 2 and 3 showing mild apical staining in dysplastic cells. B, G1-G2 pancreatic 
adenocarcinoma showing mild to moderate apical staining in neoplastic glands. C, G1-
G2 primary pancreatic adenocarcinoma showing diffuse apical positivity and focally 
extended membranous and cytoplasmic strong staining (arrows). D, G3 primary 
pancreatic adenocarcinoma showing membranous and cytoplasmic strong staining in 
neoplastic cells. E, G3 primary pancreatic adenocarcinoma discohesive tumoral cells 
showing strong membranous and cytoplasmic staining. F, Primary pancreatic 
adenocarcinoma showing admixed discohesive tumoral cells with strong cytoplasmic 
staining and neoplastic glands with mostly apical moderate staining. G, G2 pancreatic 
adenocarcinoma nodal metastasis with apical mild staining (asterisk). The adjacent 
lymphoid follicles show the expected staining of germinal centre (dendritic pattern) and 
of mantle lymphocytes. (arrows). H, G3 pancreatic adenocarcinoma nodal metastasis 
with moderate to strong membranous and cytoplasmic staining. Please note the 
positive internal control staining of nodal sinuses (arrow). I, G3 pancreatic 
adenocarcinoma nodal metastasis with discohesive tumoral cells with strong 
membranous and moderate cytoplasmic staining. 
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TABLES 
 
Table 1. CD73 expression in hepatobiliopancreatic neoplastic lesions. 
Lesion 
 
Staining pattern  
In normal counterpart 
Staining Pattern in lesion 
 
CD73+ 
cases 
 
CD73+ TC% 
 
CD73 
intensity 
 
CD73+ intensity=3 
 
 
 
 
N / tot (%) Median 
(range) 
Median 
(range) 
N / tot (%) 
Liver 
HCC Canalicular (hepatocyte) Canalicular/membranous/ cytoplasmic 24/24 (100) 80 (10-95) 2 (1-3) 15/24 (63) 
ICC Apical (cholangiocyte) Apical/ focally membranous or 
cytoplasmic 
20/24 (83) 45 (5-95) 1.5 (1-2) 9/24 (38) 
Extrahepatic Bile duct 
BilIN Apical (cholangiocyte) Apical 5/9 (56) 5 (5-30) 1 (1) 0 
Carcinoma Apical (cholangiocyte) Apical/ focally membranous or 
cytoplasmic 
25/25 (100) 40 (10-95) 1.5 (1-2.5) 8/25 (32) 
Pancreas 
PDAC Apical (pancreatic duct cell) Apical/membranous/cytoplasmic 42/42 (100) 80 (5-95) 2 (1-3) 26/42 (62) 
MCA Apical (pancreatic duct cell) Apical 1/5 (20) 80 (80) 1.5 (1.5) 0 
IPMN Apical (pancreatic duct cell) Apical 10/13 (77) 30 (5-90) 1 (0.5-1) 0 
PanNET/PanNEC Negative (endocrine islets 
cell) 
Membranous/cytoplasmic 8/23 (35) 27.5 (10-95) 1.75 (1-2) 1/23 (4) 
ACC Negative (acinic cell) Membranous/cytoplasmic 2/19 (10) 7.5 (5-10) 2.25 (2-2.5) 1/19 (5) 
Legend: ACC: acinar cell carcinoma; BilIN: biliary intraductal neoplasia; ICC: cholangiocellular carcinoma; HCC: hepatocellular carcinoma; IPMN: intraductal 
papillary mucinous neoplasm; MCA: mucinous cystadenoma; NA: not applicable; PDAC: pancreatic ductal adenocarcinoma; PanNET/PanNEC: pancreatic 
neuroendocrine tumor/ pancreatic neuroendocrine carcinoma; TC: tumor cells. 
  
Tables 1, 2, 3 Click here to access/download;Table;CD73 HBP Tables 10.12.docx
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Table 2. CD73 expression in PanIN, G1-G2 and G3 primary and metastatic PDAC areas. 
Tumor area CD73+ 
 
 
CD73+ TC% 
 
 
CD73 intensity 
 
CD73+ TC% intensity=3 
 
 N / tot (%) Median (range) Median (range) N / tot (%) 
PanIN  12/14 (86) 30 (10-95) 1 (1-1.5) 0 
Primary G1-G2 37/37 (100) 70 (5-95) 1 (1-2) 15/37 (41) 
Primary G3 25/25 (100) 95 (75-95) 3 (1.5-3) 25/25 (100) 
Metastasis G1-G2 8/8 (100) 17 (10-90) 1 (1-1.5) 0 
Metastasis G3 4/4 (100) 95 (90-95) 2.3 (2-2.5) 4/4 (100) 
Legend: PanIN: pancreatic intraepithelial neoplasia; PDAC: pancreatic ductal adenocarcinoma; TC: tumor cells. 
  
3 
 
Table 3. CD73 expression in TIMC. 
Lesion 
 
TIMC quantity  
 
 CD73+ TIMC % 
 
 (1/2/3) Median (range) 
Liver   
HCC 16/4/4 1 (1-20) 
ICC 17/7/0 2 (1-10) 
Extrahepatic Bile duct 
Bile duct carcinoma 21/2/0 5 (1-10) 
Pancreas   
PDAC 19/20/3 3 (1-20) 
PanNET/PanNEC 22/1/0 1 (1-5) 
ACC 19/19 1 (1) 
Legend: ACC: acinar cell carcinoma; ICC: cholangiocellular carcinoma; HCC: hepatocellular carcinoma; PDAC: 
pancreatic ductal adenocarcinoma; PanNET/PanNEC: pancreatic neuroendocrine tumor/pancreatic neuroendocrine 
carcinoma; TIMC: tumor infiltrating mononuclear cells. 
 
Figure 1 Click here to access/download;Figure;Fig.1.TIF
Figure 2 Click here to access/download;Figure;Fig.2.TIF
Figure 3 Click here to access/download;Figure;Fig.3.TIF
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SUPPLEMENTARY MATERIAL 
 
Supp. Table 1. Clinico-pathological features. 
Lesion 
 
Gender 
 
Age 
 
pT1-T2 
 
pN+ 
 
pM+ 
 
G1-G2 
 
MVI+ 
   M:F (ratio) median (range) N (%) N (%) N (%) N (%) N (%) 
HCC 17:7 (2.4) 63.5 (21-79) 19 (79) 1 (4) 2 (8) 17 (71) 11 (46) 
ICC 14:10 (1.4) 69 (50-83) 13 (54) 8 (33) 2 (8) 17 (71) 16 (67) 
Bile duct 
carcinoma 
14:11 (1.3) 67 (42-80) 12 (48) 17 (68) 1 (4) 15 (60) 19 (76) 
PDAC 27:15 (1.8) 68 (43-85) 29 (69) 36 (86) 6 (14) 20 (48) 32 (76) 
Pancreatic MCA 0:5 60 (42-65) NA NA NA NA NA 
Pancreatic IPMN 7:5 (1.4) 71 (41-78) NA NA NA NA NA 
PanNET/PanNEC 13:10 (1.3) 52 (34-82) 12 (52) 9 (39) 2 (9) 19 (83) 13 (56) 
Pancreatic ACC 16:3 (5.3) 67 (49-84) 10 (53) 5 (26) 8 (42) NA 8 (42) 
Legend: ACC: acinar cell carcinoma; HCC: hepatocellular carcinoma; ICC: cholangiocellular carcinoma; IPMN: 
intraductal papillary mucinous neoplasm; MCA: mucinous cystadenoma; MVI: microvascular invasion; NA: not 
assessable; PanIN: pancreatic intraductal neoplasia; PDAC: pancreatic ductal adenocarcinoma; 
PanNET/PanNEC: pancreatic neuroendocrine tumor/ pancreatic neuroendocrine carcinoma. 
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Supp. Table 2. CD73 expression in PDAC cases, according to PanIN, G1-G2 and G3 areas, and in paired metastatic deposits. 
 
Case Tumor PanIN  
 
PanIN  G1-G2  
 
G1-G2  G3  G3  Metastasis Metastasis  Metastasis  
Grade CD73+ TC% CD73 intensity CD73+ TC% CD73 intensity CD73+ TC% CD73 intensity grade CD73+ TC% CD73 intensity 
1 G2-G3 30 1 30 1.5 90 2 G1-G2 90 1 
2 G2-G3 NA NA 80 1.5 95 3       
3 G2-G3 NA 1.5 80 2 90 2.5       
4 G2-G3 NA NA 50 1 90 2.5 G1-G2 15 1 
5 G2-G3 10 NA 30 1 90 2.5       
6 G2-G3 30 NA 85 2 90 3 G3 95 2.5 
7 G2-G3 NA NA 80 2 90 3       
8 G2-G3 90 NA 70 1.5 95 1.5       
9 G2-G3 NA NA 70 1.5 80 2.5       
10 G2-G3 80 1 40 1 80 2 G1-G2 70 1 
11 G2-G3 0 1.5 80 1.5 90 2.5 G1-G2 70 1.5 
12 G2-G3 80 NA 80 1.5 90 2.5 G3 95 2 
13 G2-G3 NA NA 60 1 70 2.5 G3 95 2.5 
14 G2-G3 NA NA 80 1 95 3       
15 G2-G3 95 1 90 1.5 95 2       
16 G2-G3 NA NA 95 2.5 90 3       
17 G2-G3 NA NA 5 1 70 1.5       
18 G2-G3 30 1.5 40 1.5 40 1.5       
19 G2-G3 NA NA 70 1.5 70 3       
20 G2-G3 NA NA 30 1 40 1.5       
21 G1-G2 NA NA 85 1.5 NA NA G1-G2 10 1 
3 
 
22 G1-G2 NA NA 70 1 NA NA G1-G2 15 1 
23 G1-G2 NA NA 80 1 NA NA       
24 G1-G2 NA NA 0 0 NA NA       
25 G1-G2 30 0 65 1 NA NA       
26 G1-G2 15 1 80 1.5 NA NA       
27 G1-G2 NA 1 90 1.5 NA NA       
28 G1-G2 NA NA 70 1 NA NA       
29 G1-G2 NA 1.5 50 1 NA NA G1-G2 15 1 
30 G1-G2 NA 1 60 1 NA NA       
31 G1-G2 NA NA 80 2 NA NA       
32 G1-G2 90 NA 80 1.5 NA NA       
33 G1-G2 NA NA 60 1 NA NA G1-G2 20 1 
34 G1-G2 NA NA 80 1.5 NA NA G3 90 2 
35 G1-G2 30 1 30 1.5 NA NA       
36 G1-G2 NA NA 60 2 NA NA       
37 G1-G2 NA NA NA NA 90 2.5       
38 pure G3 NA 1 NA NA 70 2       
39 pure G3 0 NA NA NA 95 3       
40 pure G3 NA 0 NA NA 95 3       
41 pure G3 NA NA NA NA 95 3       
42 pure G3 NA NA NA NA 95 3       
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Supp. Table 3. Cox univariate analysis for hepatobiliary malignancies. 
 
Variable (category) HR IC 95% p-value 
Age 1.014 (0.985 - 1.044) 0.352 
Gender (Male) 0.720 (0.351 - 1.477) 0.370 
Pathological T stage (pT3-pT4) 2.242 (1.165 - 4.315) 0.016 
Pathological Nodal status (positive) 4.283 (2.047 - 8.962) < 0.001 
Pathological Metastatic disease 0.955 (0.334 - 2.733) 0.932 
Microvascular invasion 2.760 (1.290 - 5.904) 0.009 
Tumor grade (G2-G3) * 2.463 (1.213 - 5.001) 0.013 
CD73+TC% 1.010 (1.001 - 1.020) 0.032 
CD73 intensity 1.489 (0.979 - 2.263) 0.063 
CD73+TC% intensity=3 1.026 (1.008 - 1.045) 0.006 
* ACC were not included for the analysis of this parameter. 
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Supp. Table 4. Cox univariate analysis for HCC, ICC, Bile duct carcinoma, PDAC, and ACC. 
Variable HCC ICC Bile duct carcinoma PDAC ACC 
  HR 95,0% IC  p-value HR 95,0% IC  p-value HR 95,0% IC  p-value HR 95,0% IC  p-value HR 95,0% IC  p-value 
Age 1.00 (0.9-1.1) 0.95 1.16 (1-1.4) 0.14 0.96 (0.9-1) 0.18 1.02 (1-1.1) 0.46 1.07 (0.9-1.2) 0.31 
Gender (Male) NA   0.68 (0.1-8.7) 0.776 1.11 (0.3-4.7) 0.89 2.58 (0.6-11.8) 0.22 0.65 (0.7-6.3) 0.65 
Pathological T 
stage (pT3-pT4) 
2.47 (0.4-15.3) 0.33 NA     0.34 (0.1-2) 0.24 0.79 (0.2-2.6) 0.7 0.16 (0-1.5) 0.11 
Pathological Nodal 
status (positive) 
NA     11.9 (1.2-117.7) 0.03 2.7 (0.5-14.4) 0.25 1.41 (0.2-11.1) 0.74 2.17 (0.3-15.4) 0.44 
Pathological 
Metastatic disease 
NA     NA     NA     4.27 (0.7-25.6) 0.11 0.91 (0.1-6.5) 0.93 
Microvascular 
invasion 
1.92 (0.2-22.1) 0.6 1.79 (0.2-17.3) 0.62 1.64 (0.3-9.4) 0.58 29.59 (0.1-10671.9) 0.26 3.46 (0.6-21.7) 0.19 
Tumor grade  
(G2-G3) 
4.14 (0.5-37.9) 0.21 0.73 (0.1-7.2) 0.79 1.39 (0.3-7.4) 0.7 1.2 (0.4-3.8) 0.76 NA     
CD73+TC% 0.96 (0.9-1) 0.04 1.01 (1-1) 0.6 1.00 (1-1) 0.79 1.07 (1-1.1) 0.02 1.02 (0.8-1.4) 0.89 
CD73 intensity 0.01 (0-0.6) 0.03 1.52 (0.3-9) 0.64 1.86 (0.4-9.4) 0.46 1.41 (0.5-3.8) 0.5 1.3 (0.5-3.5) 0.6 
CD73+TC% 
intensity=3 
0.97 (0.9-1.1) 0.67 1.00 (0.8-1.3) 0.99 1.00 (1-1) 0.97 1.02 (1-1) 0.08 0.86 (0.4-1.9) 0.69 
Legend: ACC: acinar cell carcinoma; ICC: cholangiocellular carcinoma; HCC: hepatocellular carcinoma; MVI: microvascular invasion; NA: not applicable (insufficient number of 
cases or events); PDAC: pancreatic ductal adenocarcinoma; TC: tumor cells. 
6 
 
Figure S1. CD73 mRNA levels in tumors according to public datasets 
accessible from cBioPortal. 
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Figure S2. Visual references for the analysis of specimens.  
 
A-C, Quantity of tumor infiltrating mononuclear cells (TIMC) was semiquantitatively 
scored in a three tiers system: A, scattered (score=1); B, easy to find (score=2); C 
extension similar to that of tumor cells (score=3). D-F, Intensity of CD73 staining was 
also evaluated in a three tiers system: D, mild (score=1); E, moderate (score=2) and 
F, strong (score=3). 
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Fig. S3. CD73 in normal hepatobiliopancreatic tissues. 
 
A, Normal liver lobule showing moderate canalicular staining of hepatocytes (arrows) 
and endothelial sinusoidal staining (arrowheads). B, Normal liver portal tract showing 
mild apical staining in bile ducts epithelium (arrows). C, Normal common bile duct 
showing mild apical staining in the epithelial lining. D, Normal bile ducts showing no 
CD73 staining in the presence a positive internal control (endothelial staining in the 
adjacent vessel, arrow). E, Normal pancreas, showing mild apical staining of a large 
pancreatic duct (centre) and adjacent endothelial vascular staining. F, Normal 
pancreas, showing negative staining in pancreatic acini and Langerhans islet 
(asterisk) in the presence of positive internal controls (endothelial and stromal staining, 
arrows). 
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Figure S4. Diagram of CD73 analysis in PDAC specimens. 
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Figure S5. CD73 in pancreatic mucinous lesions, neuroendocrine tumors and 
acinar cell carcinoma. 
 
A, Mucinous cystadenoma showing mild (score 1) apical expression in dysplastic cells. 
B, Intraductal Papillary Mucinous Neoplasia showing focal moderate apical expression 
in dysplastic cells. C, G2 pancreatic neuroendocrine tumor showing heterogeneous 
moderate (score 2) membranous and cytoplasmic expression in neoplastic cells. D, 
Acinar cell carcinoma showing absence of expression in neoplastic cells. 
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Figure S6. Cumulative overall survival rates for hepatobiliopancreatic 
malignancies, based on CD73 expression (Kaplan-Meier plot). 
 
In hepatobiliopancreatic malignancies, the presence of <50% of CD73+ tumor cells 
(TC) (continuous line) significantly associated with longer overall survival, as 
compared with cases with ≥50 of CD73+ TC (p = 0.041, log-rank test). 
  
12 
Figure S7. E-Cadherin and CD73 expression PDAC. 
A, Non-neoplastic pancreas showing preserved membranous E-Cadherin (purple), 
without any detectable CD73 staining. B, Moderately differentiated (G2) PDAC 
showing preserved membranous E-Cadherin and coexistent membranous CD73 
staining (yellow). C, Poorly differentiated (G3) PDAC showing a 
membranous/cytoplasmic CD73 staining associated with a focal loss of E-Cadherin 
(focal EMT phenotype). D, Poorly differentiated (G3) PDAC showing a 
membranous/cytoplasmic CD73 staining associated with a diffuse loss of E-Cadherin 
(extensive EMT phenotype). 
